Histology and p53 immunohistochemistry in biopsy series of cases and controls
| Controls | Cases | RR (95% CI) | RR* (95% CI) | |
|---|---|---|---|---|
| n=1300 | n=132 | |||
| Histology | ||||
| ND | 1011 (78%) | 74 (56%) | Reference | Reference |
| LGD | 289 (22%) | 58 (44%) | 4.2 (2.4 to 7.3) | 4.0 (2.3 to 7.0) |
| P53 immunohistochemistry | ||||
| Normal p53 expression | 1115 (86%) | 67 (51%) | Reference | Reference |
| Aberrant p53 expression | 185 (14%) | 65 (49%) | 6.2 (3.6 to 10.9) | 6.4 (3.6 to 11.3) |
| P53 overexpression | 169 (13%) | 58 (44%) | 5.5 (3.1 to 10.0) | 5.6 (3.1 to 10.3) |
| Loss of p53 expression | 16 (1%) | 7 (5%) | 13.4 (5.1 to 35.3) | 14.0 (5.3 to 37.2) |
| Histology and p53 immunohistochemistry | ||||
| ND and normal p53 expression | 918 (71%) | 50 (38%) | Reference | Reference |
| LGD and normal p53 expression | 197 (15%) | 17 (13%) | 2.4 (0.9 to 6.0) | 2.2 (0.8 to 5.5) |
| ND and aberrant p53 expression | 93 (7%) | 24 (18%) | 4.5 (2.0 to 10.0) | 4.3 (1.9 to 9.8) |
| LGD and aberrant p53 expression | 92 (7%) | 41 (31%) | 11.2 (5.7 to 22.0) | 12.2 (6.1 to 24.5) |
*Adjusted for age, gender, Barrett length and oesophagitis.
The highest degree of abnormality was reported for each endoscopy after examining all biopsies.
Loglinear regression models were used to calculate relative risks (RRs) and CIs for neoplastic progression.
LGD, low-grade dysplasia; ND, no dysplasia.